MGX

0.56507.95%
JI

Jian Irish

CEO, President & Director

Dr. Jian Irish, Ph.D., MBA, is CEO of Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) from November 2025 and serves as its Director. She served as Chief Operating Officer at Metagenomi Therapeutics, Inc. (formerly known as Metagenomi, Inc.) since January 2021 until November 2025 and has been its President since November 2021. Dr. Irish serves as a Manufacturing Advisor at Oribiotech Ltd. Dr. Irish has many years of biopharma leadership experience in operations and drug development. At Metagenomi, she oversees organizational development and the operationalization of Metagenomi’s gene editing technologies to pivot towards therapeutic advancements. She served as Senior Vice President of Supply Chain at Kite Pharma, Inc. since December 1, 2016 until October 2, 2017. Dr. Irish established her career in the biopharmaceutical industry through various global leadership roles. She joins Kite from Sanofi, where she served as the Vice President of Biologics Strategic Supply, Sourcing and Partnerships. She served as Vice President of Biologics Product Development Technology Transfer at Sanofi. In these roles, Dr. Irish oversaw the strategy and execution of the Biologics supply chain and technical transfer processes to scale up Sanofi Biological operations. Prior to Sanofi, Dr. Irish was the Executive Director, General Manager of Japan Asia Pacific Supply Chain at Amgen as well as the Executive Director, Global Head of Contract Manufacturing where Dr. Irish made a critical impact in the commercialization of Vectibix, Xgeva and Enbrel. she served s Global Head of Manufacturing at Kite Pharma, Inc n these roles she led the launch of one of the first two CAR-T cell therapies and oversaw the company’s expansion of its global footprint, including EMA approval of the first commercial cell therapy manufacturing facility in Europe. Dr. Irish holds a Bachelor of Science in Chemical Engineering from East China University of Science and Technology in Shanghai, China, a Master of Science and Ph.D. in Pharmaceutical Sciences from Chiba University in Chiba, Japan and a Master of Business Administration from the Anderson School of Management at University of California, Los Angeles.

Positions